PUBLISHER: DelveInsight | PRODUCT CODE: 1120515
PUBLISHER: DelveInsight | PRODUCT CODE: 1120515
DelveInsight's, "Spinocerebellar Ataxias - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Spinocerebellar Ataxias pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Ataxia is the absence of voluntary muscle coordination and loss of control of movement that affects gait stability, eye movement, and speech. Spinocerebellar ataxia (SCA) is an inherited (autosomal dominant), progressive, neurodegenerative, and heterogeneous disease that mainly affects the cerebellum. SCA is a subset of hereditary cerebellar ataxia and is a rare disease. SCA is a subset of hereditary cerebellar ataxia and is a rare disease. To date, more than 40 distinct genetic SCAs have been identified which are classified according to the genetic loci in order of identification. SCA1 was the first SCA described and then further subtypes are identified sequentially. SCA doesn't compulsorily mean that it is restricted to the cerebellum and spinal cord. It may involve the other parts of the central nervous system as well, such as pontine nuclei, spinal cord, peripheral nerves, cortex, basal ganglia, etc. SCA6 is restricted to the cerebellum whereas SCA2 spares cerebellum.
"Spinocerebellar Ataxias - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spinocerebellar Ataxias pipeline landscape is provided which includes the disease overview and Spinocerebellar Ataxias treatment guidelines. The assessment part of the report embraces, in depth Spinocerebellar Ataxias commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinocerebellar Ataxias collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Spinocerebellar Ataxias R&D. The therapies under development are focused on novel approaches to treat/improve Spinocerebellar Ataxias.
This segment of the Spinocerebellar Ataxias report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Troriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. The primary mode of action of troriluzole is reducing synaptic levels of glutamate. Troriluzole increases glutamate uptake from the synapse, by augmenting the expression and function of excitatory amino acid transporters located on glial cells that play a key role in clearing glutamate from the synapse. Troriluzole has the potential to be developed in a number of other diseases associated with excessive glutamate. Currently, the drug is in Phase III stage of clinical trial evaluation for the treatment of Spinocerebellar Ataxias.
This segment of the report provides insights about the Spinocerebellar Ataxias drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 12+ key companies which are developing the therapies for Spinocerebellar Ataxias. The companies which have their Spinocerebellar Ataxias drug candidates in the most advanced stage, i.e. Phase III include Biohaven Pharmaceuticals.
DelveInsight's report covers around 15+ products under different phases of clinical development like:
Spinocerebellar Ataxias pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
Products have been categorized under various Molecule types such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinocerebellar Ataxias therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinocerebellar Ataxias drugs.